Results 151 to 160 of about 7,774 (200)

Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera. [PDF]

FEBS J
Sin YY, Giblin A, Judina A, Rujirachaivej P, Corral LG, Glennon E, Tai ZX, Feng T, Torres E, Zorn A, Gorelik J, Kyurkchieva E, Yenchitsomanus PT, Swindlehurst C, Chan K, Stirling D, Baillie GS.   +16 more
europepmc   +1 more source

Understanding the Potential of Antibody‐Drug Conjugates Functionalized Engineered Exosomes in Hepatocellular Carcinoma Therapy: A Comprehensive Narrative Review

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Exosomes are naturally secreted nanovesicles with high biocompatibility, low immunogenicity, and the ability to traverse biological barriers, making them attractive theragnostic carriers. When engineered to present tumor‐specific antibodies and to deliver antibody‐drug conjugates (ADCs), they may enhance selective targeting of ...
Subham Sarkar, Avinaba Bose, Jenifer Rajak, Arup Kumar Mitra, Ajoy Kumer, Bikram Dhara   +5 more
wiley   +1 more source

Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC). [PDF]

J Med Chem
Monsen PJ, Bommi PV, Grigorescu AA, Lauing KL, Mao Y, Berardi P, Zhai L, Ojo O, Penco-Campillo M, Koch T, Egozi M, Jha S, Dunne SF, Jiang H, Song G, Zhang F, Kregel S, Vaziri-Gohar A, Fanning SW, Sanchez-Gomez P, Allen JM, Yamini B, Lukas RV, Wainwright DA, Schiltz GE.   +24 more
europepmc   +1 more source

Sigma‐1 Receptor‐Targeting Compounds Show Antiviral Activity Across Multiple Coronavirus Models

Journal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Over the past two decades, coronaviruses have caused three major public health crises, including the epidemics of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2. Following the outbreak of SARS‐CoV‐2, several antiviral drugs have been approved for the treatment of COVID‐19.
Cuiling Zhang, Xingpeng Dong, Jiaying Liu, Minghua chen, Lisen Lin, Gaojie Song, Xianzhu Xia, Gaoxing Su, Xiao Li, Chao Shang   +9 more
wiley   +1 more source

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. [PDF]

ChemMedChem
Almodóvar-Rivera CM, Tandon I, Mudududdla R, Esguerra PN, Lucio-Acero K, Tang W.   +5 more
europepmc   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta, Ramakrishna Vadde, Ganji Purnachandra Nagaraju   +2 more
wiley   +1 more source

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. [PDF]

Mol Cancer Ther
Snyder LB, Neklesa TK, Willard RR, Gordon DA, Pizzano J, Vitale N, Robling K, Dorso MA, Moghrabi W, Landrette S, Gedrich R, Lee SH, Taylor ICA, Houston JG.   +13 more
europepmc   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Preparation and Characterization of Ternary Complexes to Improve the Solubility and Dissolution Performance of a Proteolysis-Targeting Chimera Drug. [PDF]

Pharmaceutics
Zhang H, Wu H, Wang L, Galarza LM, Wu C, Li M, Wang Z, Zhou E, Han J.   +8 more
europepmc   +1 more source

Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
Colorectal cancer is a heterogeneous, adaptive disease shaped by population‐level risk, genomic and epigenetic alterations, tumor ecosystem evolution, and treatment pressure. This review integrates epidemiology, risk factors, signaling networks, clinical presentation, screening, molecular diagnosis, and stage‐ and biomarker‐guided management while ...
Kairui Wan, Ke Tang, Linglong Wang, Qin Tian, Mingwei Zheng, Cheng Qian, Limei Liu   +6 more
wiley   +1 more source